A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer
- Creators
- Kim, Esther
-
Ahn, Hyeok
-
Park, Hansoo
Abstract
Gut microbiota has been studied in relation to human health and disease prediction for decades. Also, immune checkpoints (ICPs) are enthusiastically investigated for anti-tumor immunotherapy. Recent studies show potential of gut microbiome and gut cytokines as biomarkers for carcinogenesis and response prediction of immune checkpoint inhibitor (ICI) response. Evidence has revealed that intestinal microorganisms play a major role in the effectiveness of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade. In this review, we have focused on how microbiome and microbiome-generated cytokines affect immune checkpoints. We have also described the molecular mechanisms behind this interplay and the bacterial strains that have a potential role in immunotherapy.
Additional Information
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Received 01 December 2020; Accepted 17 March 2021; Published 30 March 2021. This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Ministry of Science & ICT (Grant Number: NRF-2017M3A9F3046536), a GIST Research Institute (GRI) grant, funded by the GIST in 2020. This research was supported by grants from National Cancer Centre, Korea (NCC-1911267). Author Contributions: EK and HA wrote the manuscript. HP revised the manuscript. The authors declare that they have no conflict of interest.Attached Files
Published - Kim2021_Article_AReviewOnTheRoleOfGutMicrobiot.pdf
Files
| Name | Size | Download all |
|---|---|---|
|
md5:b422be38db0db509ed20ad0ebaf4e4c2
|
644.2 kB | Preview Download |
Additional details
- PMCID
- PMC8295158
- Eprint ID
- 108591
- Resolver ID
- CaltechAUTHORS:20210331-084638621
- NRF-2017M3A9F3046536
- National Research Foundation of Korea
- Gwangju Institute of Science and Technology
- NCC-1911267
- National Cancer Centre (Korea)
- Created
-
2021-04-09Created from EPrint's datestamp field
- Updated
-
2023-07-17Created from EPrint's last_modified field